PLoS ONE (Jan 2012)

Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells.

  • Yan Shi,
  • Bin Tang,
  • Pei-Wu Yu,
  • Bo Tang,
  • Ying-Xue Hao,
  • Xiao Lei,
  • Hua-Xing Luo,
  • Dong-Zhu Zeng

DOI
https://doi.org/10.1371/journal.pone.0051076
Journal volume & issue
Vol. 7, no. 11
p. e51076

Abstract

Read online

Oxaliplatin is included in a number of effective combination regimens used as first and subsequent lines of therapy for metastatic colorectal cancer. Accumulating evidence indicates that autophagy plays a significant role in response to cancer therapy. However, the role of autophagy in oxaliplatin-induced cell death remains to be clarified. In this study, we showed that oxaliplatin induced cell death and autophagy in Caco-2 colorectal cancer cells. The suppression of autophagy using either pharmacologic inhibitors (3-methyladenine, bafilomycin A1) or RNA interference in essential autophagy genes (ATG5 or Beclin1) enhanced the cell death and reactive oxygen species (ROS) production induced by oxaliplatin in Caco-2 cells. Blocking oxaliplatin-induced ROS production by using ROS scavengers (NAC or Tiron) decreased autophagy. Furthermore, numerous dilated endoplasmic reticula (ER) were present in oxaliplatin-treated Caco-2 cells, and blocking ER stress by RNA interference against candidate of metastasis-1 (P8) and C/EBP-homologous protein (CHOP) decreased autophagy and ROS production. Taken together, these data indicate that oxaliplatin activates autophagy as a cytoprotective response via ER stress and ROS in human colorectal cancer cells.